Cinpanemab scFv-Transferrin Fusion for Barrier Crossing and Cell Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells due to their size and lack of transcytosis, limiting their efficacy and application in certain diseases.
Innovation Solution
A single-chain variable fragment (scFv) antibody is designed to conjugate with the N-methyl lobe of transferrin protein, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake and transcytosis, with cleavable linkers ensuring targeted delivery and release within specific cellular environments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a whole antibody is used for therapeutic delivery, then effector functions and half-life are improved, but penetration across biological barriers and cellular uptake are reduced
Solution Approach 1:
The patent segments the antibody into its functional components: the scFv (single-chain variable fragment) containing the antigen-binding variable regions is separated from the Fc region. This segmentation allows the scFv to penetrate biological barriers effectively while the Fc region's functions are replaced by transferrin conjugation for delivery enhancement.
Solution Approach 2:
The patent introduces transferrin as an intermediary molecule that mediates the delivery of the scFv across biological barriers. The transferrin-conjugated scFv utilizes the transferrin receptor-mediated transcytosis pathway, allowing the therapeutic agent to cross barriers like the blood-brain barrier and enter cells efficiently.
2Length of moving object
If an scFv is used to improve penetration and tissue access, then barrier crossing ability is improved, but effector functions and half-life are reduced
Solution Approach 1:
Transferrin serves as an intermediary that provides both barrier-crossing capability and extended circulation time. The transferrin-conjugated scFv utilizes the transferrin receptor-mediated transcytosis pathway for efficient barrier crossing while also benefiting from transferrin's ability to extend half-life through receptor-mediated recycling.
3Length of moving object
If an scFv is used to improve penetration and tissue access, then barrier crossing ability is improved, but therapeutic efficacy is reduced
Solution Approach 1:
The patent merges the antigen-binding function of the scFv with the delivery-enhancing properties of transferrin into a single fusion protein. This combination allows the molecule to simultaneously achieve efficient barrier crossing, cellular uptake, and therapeutic activity against the target antigen.
Solution Approach 2:
Transferrin acts as an intermediary that enhances the therapeutic efficacy of the scFv by facilitating its delivery across biological barriers and into target cells, thereby ensuring the scFv reaches its therapeutic target effectively.
4Length of moving object
If transferrin conjugation is used to enhance transcytosis, then barrier penetration is improved, but off-target effects may increase
Solution Approach 1:
The patent applies local quality by using cleavable linkers that are specifically activated in the target tissue microenvironment. These linkers remain intact during circulation and barrier crossing but are cleaved by enzymes or pH changes specific to the target tissue, enabling localized release of the scFv and minimizing off-target effects.
Data Source
AI summary
The efficacy and indication of cinpanemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.